nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP1B1—Mitoxantrone—multiple sclerosis	0.233	0.327	CbGbCtD
Flutamide—CYP1B1—Dexamethasone—multiple sclerosis	0.121	0.17	CbGbCtD
Flutamide—CYP1A1—Dexamethasone—multiple sclerosis	0.0529	0.0744	CbGbCtD
Flutamide—CYP3A4—Fingolimod—multiple sclerosis	0.0508	0.0714	CbGbCtD
Flutamide—CYP2C19—Prednisone—multiple sclerosis	0.041	0.0577	CbGbCtD
Flutamide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0328	0.046	CbGbCtD
Flutamide—CYP3A5—Dexamethasone—multiple sclerosis	0.0318	0.0446	CbGbCtD
Flutamide—CYP2C19—Dexamethasone—multiple sclerosis	0.0256	0.036	CbGbCtD
Flutamide—CYP3A4—Triamcinolone—multiple sclerosis	0.0248	0.0349	CbGbCtD
Flutamide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0239	0.0336	CbGbCtD
Flutamide—CYP3A4—Betamethasone—multiple sclerosis	0.0213	0.0299	CbGbCtD
Flutamide—CYP3A4—Prednisolone—multiple sclerosis	0.021	0.0295	CbGbCtD
Flutamide—CYP3A4—Prednisone—multiple sclerosis	0.0198	0.0279	CbGbCtD
Flutamide—CYP3A4—Dexamethasone—multiple sclerosis	0.0124	0.0174	CbGbCtD
Flutamide—Ill-defined disorder—Cladribine—multiple sclerosis	0.000766	0.00359	CcSEcCtD
Flutamide—Anaemia—Cladribine—multiple sclerosis	0.000763	0.00357	CcSEcCtD
Flutamide—Headache—Fingolimod—multiple sclerosis	0.000745	0.00349	CcSEcCtD
Flutamide—Malaise—Cladribine—multiple sclerosis	0.000745	0.00349	CcSEcCtD
Flutamide—Increased appetite—Triamcinolone—multiple sclerosis	0.000724	0.00339	CcSEcCtD
Flutamide—Increased appetite—Methylprednisolone—multiple sclerosis	0.000722	0.00338	CcSEcCtD
Flutamide—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.000718	0.00336	CcSEcCtD
Flutamide—Dermatitis bullous—Triamcinolone—multiple sclerosis	0.000712	0.00333	CcSEcCtD
Flutamide—Diabetes mellitus—Dexamethasone—multiple sclerosis	0.00071	0.00332	CcSEcCtD
Flutamide—Diabetes mellitus—Betamethasone—multiple sclerosis	0.00071	0.00332	CcSEcCtD
Flutamide—Hyperglycaemia—Mitoxantrone—multiple sclerosis	0.000703	0.00329	CcSEcCtD
Flutamide—Anxiety—Cladribine—multiple sclerosis	0.000701	0.00328	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000698	0.00327	CcSEcCtD
Flutamide—Discomfort—Cladribine—multiple sclerosis	0.000695	0.00325	CcSEcCtD
Flutamide—Drowsiness—Mitoxantrone—multiple sclerosis	0.000695	0.00325	CcSEcCtD
Flutamide—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000689	0.0092	CbGpPWpGaD
Flutamide—Confusional state—Cladribine—multiple sclerosis	0.00068	0.00318	CcSEcCtD
Flutamide—Jaundice—Mitoxantrone—multiple sclerosis	0.000677	0.00317	CcSEcCtD
Flutamide—Oedema—Cladribine—multiple sclerosis	0.000674	0.00316	CcSEcCtD
Flutamide—Ecchymosis—Prednisone—multiple sclerosis	0.000669	0.00313	CcSEcCtD
Flutamide—Haematuria—Mitoxantrone—multiple sclerosis	0.000662	0.0031	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000662	0.00884	CbGpPWpGaD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000662	0.00884	CbGpPWpGaD
Flutamide—Thrombocytopenia—Cladribine—multiple sclerosis	0.00066	0.00309	CcSEcCtD
Flutamide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000659	0.00881	CbGpPWpGaD
Flutamide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000659	0.00881	CbGpPWpGaD
Flutamide—Increased appetite—Betamethasone—multiple sclerosis	0.000657	0.00307	CcSEcCtD
Flutamide—Increased appetite—Dexamethasone—multiple sclerosis	0.000657	0.00307	CcSEcCtD
Flutamide—Skin disorder—Cladribine—multiple sclerosis	0.000655	0.00306	CcSEcCtD
Flutamide—Ulcer—Methotrexate—multiple sclerosis	0.000654	0.00306	CcSEcCtD
Flutamide—CYP1A1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000651	0.00869	CbGpPWpGaD
Flutamide—CYP1A1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000651	0.00869	CbGpPWpGaD
Flutamide—Dermatitis bullous—Dexamethasone—multiple sclerosis	0.000646	0.00302	CcSEcCtD
Flutamide—Dermatitis bullous—Betamethasone—multiple sclerosis	0.000646	0.00302	CcSEcCtD
Flutamide—Anorexia—Cladribine—multiple sclerosis	0.000643	0.00301	CcSEcCtD
Flutamide—Hepatitis—Mitoxantrone—multiple sclerosis	0.000624	0.00292	CcSEcCtD
Flutamide—Ill-defined disorder—Azathioprine—multiple sclerosis	0.000623	0.00292	CcSEcCtD
Flutamide—Anaemia—Azathioprine—multiple sclerosis	0.000621	0.00291	CcSEcCtD
Flutamide—Pulmonary embolism—Methotrexate—multiple sclerosis	0.000619	0.0029	CcSEcCtD
Flutamide—Diabetes mellitus—Prednisone—multiple sclerosis	0.000618	0.00289	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000614	0.0082	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000613	0.00818	CbGpPWpGaD
Flutamide—Insomnia—Cladribine—multiple sclerosis	0.00061	0.00285	CcSEcCtD
Flutamide—AR—Nuclear Receptors—VDR—multiple sclerosis	0.000609	0.00814	CbGpPWpGaD
Flutamide—Malaise—Azathioprine—multiple sclerosis	0.000606	0.00283	CcSEcCtD
Flutamide—Cystitis noninfective—Methotrexate—multiple sclerosis	0.000604	0.00283	CcSEcCtD
Flutamide—Leukopenia—Azathioprine—multiple sclerosis	0.000601	0.00281	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000601	0.00802	CbGpPWpGaD
Flutamide—Somnolence—Cladribine—multiple sclerosis	0.000599	0.00281	CcSEcCtD
Flutamide—Cystitis—Methotrexate—multiple sclerosis	0.000598	0.0028	CcSEcCtD
Flutamide—AHR—Adipogenesis—FAS—multiple sclerosis	0.000587	0.00784	CbGpPWpGaD
Flutamide—Decreased appetite—Cladribine—multiple sclerosis	0.000586	0.00274	CcSEcCtD
Flutamide—Fatigue—Cladribine—multiple sclerosis	0.000581	0.00272	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000577	0.0077	CbGpPWpGaD
Flutamide—Constipation—Cladribine—multiple sclerosis	0.000577	0.0027	CcSEcCtD
Flutamide—Increased appetite—Prednisone—multiple sclerosis	0.000572	0.00268	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000572	0.00764	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000572	0.00764	CbGpPWpGaD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000568	0.00266	CcSEcCtD
Flutamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000566	0.00756	CbGpPWpGaD
Flutamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000566	0.00756	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000565	0.00755	CbGpPWpGaD
Flutamide—Discomfort—Azathioprine—multiple sclerosis	0.000565	0.00264	CcSEcCtD
Flutamide—Bladder pain—Methotrexate—multiple sclerosis	0.000559	0.00262	CcSEcCtD
Flutamide—Neoplasm—Methotrexate—multiple sclerosis	0.000559	0.00262	CcSEcCtD
Flutamide—Ecchymosis—Methotrexate—multiple sclerosis	0.000559	0.00262	CcSEcCtD
Flutamide—Feeling abnormal—Cladribine—multiple sclerosis	0.000556	0.0026	CcSEcCtD
Flutamide—Gynaecomastia—Methotrexate—multiple sclerosis	0.000554	0.00259	CcSEcCtD
Flutamide—Erythema—Mitoxantrone—multiple sclerosis	0.000543	0.00254	CcSEcCtD
Flutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00054	0.00721	CbGpPWpGaD
Flutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00054	0.00721	CbGpPWpGaD
Flutamide—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000537	0.00251	CcSEcCtD
Flutamide—CYP1A1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000535	0.00714	CbGpPWpGaD
Flutamide—CYP1A1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000535	0.00714	CbGpPWpGaD
Flutamide—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000533	0.00711	CbGpPWpGaD
Flutamide—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000533	0.00711	CbGpPWpGaD
Flutamide—Skin disorder—Azathioprine—multiple sclerosis	0.000532	0.00249	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.000525	0.00701	CbGpPWpGaD
Flutamide—CYP1B1—Endogenous sterols—POMC—multiple sclerosis	0.000519	0.00693	CbGpPWpGaD
Flutamide—Diabetes mellitus—Methotrexate—multiple sclerosis	0.000516	0.00242	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000512	0.00683	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000511	0.00683	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000511	0.00683	CbGpPWpGaD
Flutamide—CYP1B1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000509	0.0068	CbGpPWpGaD
Flutamide—Ill-defined disorder—Mitoxantrone—multiple sclerosis	0.000504	0.00236	CcSEcCtD
Flutamide—Anaemia—Mitoxantrone—multiple sclerosis	0.000502	0.00235	CcSEcCtD
Flutamide—CYP1B1—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000502	0.0067	CbGpPWpGaD
Flutamide—Malaise—Mitoxantrone—multiple sclerosis	0.00049	0.00229	CcSEcCtD
Flutamide—Leukopenia—Mitoxantrone—multiple sclerosis	0.000486	0.00227	CcSEcCtD
Flutamide—Asthenia—Cladribine—multiple sclerosis	0.000484	0.00226	CcSEcCtD
Flutamide—AR—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.000482	0.00643	CbGpPWpGaD
Flutamide—Hyperglycaemia—Betamethasone—multiple sclerosis	0.000481	0.00225	CcSEcCtD
Flutamide—Hyperglycaemia—Dexamethasone—multiple sclerosis	0.000481	0.00225	CcSEcCtD
Flutamide—Pruritus—Cladribine—multiple sclerosis	0.000477	0.00223	CcSEcCtD
Flutamide—Hypertension—Mitoxantrone—multiple sclerosis	0.000469	0.00219	CcSEcCtD
Flutamide—Diarrhoea—Cladribine—multiple sclerosis	0.000461	0.00216	CcSEcCtD
Flutamide—CYP1B1—Biological oxidations—CYP24A1—multiple sclerosis	0.000461	0.00616	CbGpPWpGaD
Flutamide—CYP1B1—Biological oxidations—CYP27B1—multiple sclerosis	0.000461	0.00616	CbGpPWpGaD
Flutamide—Anxiety—Mitoxantrone—multiple sclerosis	0.000461	0.00216	CcSEcCtD
Flutamide—Discomfort—Mitoxantrone—multiple sclerosis	0.000457	0.00214	CcSEcCtD
Flutamide—CYP1B1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000455	0.00607	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000455	0.00607	CbGpPWpGaD
Flutamide—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000453	0.00604	CbGpPWpGaD
Flutamide—Feeling abnormal—Azathioprine—multiple sclerosis	0.000452	0.00211	CcSEcCtD
Flutamide—Confusional state—Mitoxantrone—multiple sclerosis	0.000447	0.00209	CcSEcCtD
Flutamide—Dizziness—Cladribine—multiple sclerosis	0.000446	0.00209	CcSEcCtD
Flutamide—Erythema—Prednisolone—multiple sclerosis	0.000445	0.00208	CcSEcCtD
Flutamide—Oedema—Mitoxantrone—multiple sclerosis	0.000443	0.00207	CcSEcCtD
Flutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000437	0.00584	CbGpPWpGaD
Flutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000437	0.00584	CbGpPWpGaD
Flutamide—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000434	0.00203	CcSEcCtD
Flutamide—Skin disorder—Mitoxantrone—multiple sclerosis	0.00043	0.00201	CcSEcCtD
Flutamide—Vomiting—Cladribine—multiple sclerosis	0.000429	0.00201	CcSEcCtD
Flutamide—Erectile dysfunction—Prednisone—multiple sclerosis	0.000428	0.002	CcSEcCtD
Flutamide—Rash—Cladribine—multiple sclerosis	0.000425	0.00199	CcSEcCtD
Flutamide—Dermatitis—Cladribine—multiple sclerosis	0.000425	0.00199	CcSEcCtD
Flutamide—Anorexia—Mitoxantrone—multiple sclerosis	0.000422	0.00198	CcSEcCtD
Flutamide—Headache—Cladribine—multiple sclerosis	0.000422	0.00198	CcSEcCtD
Flutamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00042	0.00561	CbGpPWpGaD
Flutamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00042	0.00561	CbGpPWpGaD
Flutamide—Hyperglycaemia—Prednisone—multiple sclerosis	0.000419	0.00196	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.000419	0.00559	CbGpPWpGaD
Flutamide—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000415	0.00554	CbGpPWpGaD
Flutamide—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000415	0.00554	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—FAS—multiple sclerosis	0.000414	0.00553	CbGpPWpGaD
Flutamide—Ill-defined disorder—Prednisolone—multiple sclerosis	0.000413	0.00193	CcSEcCtD
Flutamide—Erythema—Triamcinolone—multiple sclerosis	0.00041	0.00192	CcSEcCtD
Flutamide—Erythema—Methylprednisolone—multiple sclerosis	0.000409	0.00191	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000405	0.00189	CcSEcCtD
Flutamide—Malaise—Prednisolone—multiple sclerosis	0.000402	0.00188	CcSEcCtD
Flutamide—Nausea—Cladribine—multiple sclerosis	0.0004	0.00187	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000395	0.00527	CbGpPWpGaD
Flutamide—Somnolence—Mitoxantrone—multiple sclerosis	0.000394	0.00184	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000388	0.00518	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000388	0.00518	CbGpPWpGaD
Flutamide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000385	0.0018	CcSEcCtD
Flutamide—Hypertension—Prednisolone—multiple sclerosis	0.000385	0.0018	CcSEcCtD
Flutamide—Fatigue—Mitoxantrone—multiple sclerosis	0.000382	0.00179	CcSEcCtD
Flutamide—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00038	0.00178	CcSEcCtD
Flutamide—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000379	0.00178	CcSEcCtD
Flutamide—Constipation—Mitoxantrone—multiple sclerosis	0.000379	0.00177	CcSEcCtD
Flutamide—Diarrhoea—Azathioprine—multiple sclerosis	0.000375	0.00176	CcSEcCtD
Flutamide—Discomfort—Prednisolone—multiple sclerosis	0.000375	0.00175	CcSEcCtD
Flutamide—Erythema—Betamethasone—multiple sclerosis	0.000372	0.00174	CcSEcCtD
Flutamide—Erythema—Dexamethasone—multiple sclerosis	0.000372	0.00174	CcSEcCtD
Flutamide—Malaise—Triamcinolone—multiple sclerosis	0.000369	0.00173	CcSEcCtD
Flutamide—Malaise—Methylprednisolone—multiple sclerosis	0.000369	0.00173	CcSEcCtD
Flutamide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000365	0.00171	CcSEcCtD
Flutamide—Oedema—Prednisolone—multiple sclerosis	0.000364	0.0017	CcSEcCtD
Flutamide—Dizziness—Azathioprine—multiple sclerosis	0.000362	0.0017	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.00036	0.00481	CbGpPWpGaD
Flutamide—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000358	0.00167	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000355	0.00474	CbGpPWpGaD
Flutamide—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000354	0.00166	CcSEcCtD
Flutamide—Hypertension—Triamcinolone—multiple sclerosis	0.000354	0.00166	CcSEcCtD
Flutamide—Hypertension—Methylprednisolone—multiple sclerosis	0.000353	0.00165	CcSEcCtD
Flutamide—Vomiting—Azathioprine—multiple sclerosis	0.000349	0.00163	CcSEcCtD
Flutamide—Anxiety—Methylprednisolone—multiple sclerosis	0.000347	0.00162	CcSEcCtD
Flutamide—Drowsiness—Methotrexate—multiple sclerosis	0.000346	0.00162	CcSEcCtD
Flutamide—Rash—Azathioprine—multiple sclerosis	0.000346	0.00162	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000346	0.00162	CcSEcCtD
Flutamide—Dermatitis—Azathioprine—multiple sclerosis	0.000345	0.00162	CcSEcCtD
Flutamide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000345	0.00161	CcSEcCtD
Flutamide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000345	0.00161	CcSEcCtD
Flutamide—Discomfort—Triamcinolone—multiple sclerosis	0.000345	0.00161	CcSEcCtD
Flutamide—Discomfort—Methylprednisolone—multiple sclerosis	0.000344	0.00161	CcSEcCtD
Flutamide—Headache—Azathioprine—multiple sclerosis	0.000343	0.00161	CcSEcCtD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000341	0.00455	CbGpPWpGaD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000341	0.00455	CbGpPWpGaD
Flutamide—Confusional state—Methylprednisolone—multiple sclerosis	0.000336	0.00157	CcSEcCtD
Flutamide—Malaise—Betamethasone—multiple sclerosis	0.000335	0.00157	CcSEcCtD
Flutamide—Malaise—Dexamethasone—multiple sclerosis	0.000335	0.00157	CcSEcCtD
Flutamide—Oedema—Triamcinolone—multiple sclerosis	0.000334	0.00156	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	0.000333	0.00444	CbGpPWpGaD
Flutamide—Haematuria—Methotrexate—multiple sclerosis	0.00033	0.00154	CcSEcCtD
Flutamide—Insomnia—Prednisolone—multiple sclerosis	0.000329	0.00154	CcSEcCtD
Flutamide—Nausea—Azathioprine—multiple sclerosis	0.000326	0.00152	CcSEcCtD
Flutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000325	0.00433	CbGpPWpGaD
Flutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000325	0.00433	CbGpPWpGaD
Flutamide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000324	0.00152	CcSEcCtD
Flutamide—Erythema—Prednisone—multiple sclerosis	0.000324	0.00152	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	0.000324	0.00432	CbGpPWpGaD
Flutamide—Hypertension—Dexamethasone—multiple sclerosis	0.000321	0.0015	CcSEcCtD
Flutamide—Hypertension—Betamethasone—multiple sclerosis	0.000321	0.0015	CcSEcCtD
Flutamide—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00032	0.00428	CbGpPWpGaD
Flutamide—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00032	0.00428	CbGpPWpGaD
Flutamide—Asthenia—Mitoxantrone—multiple sclerosis	0.000318	0.00149	CcSEcCtD
Flutamide—Anxiety—Dexamethasone—multiple sclerosis	0.000315	0.00148	CcSEcCtD
Flutamide—Anxiety—Betamethasone—multiple sclerosis	0.000315	0.00148	CcSEcCtD
Flutamide—CYP1A1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000314	0.00419	CbGpPWpGaD
Flutamide—Discomfort—Dexamethasone—multiple sclerosis	0.000313	0.00146	CcSEcCtD
Flutamide—Discomfort—Betamethasone—multiple sclerosis	0.000313	0.00146	CcSEcCtD
Flutamide—Hepatitis—Methotrexate—multiple sclerosis	0.000311	0.00145	CcSEcCtD
Flutamide—CYP1A1—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000309	0.00412	CbGpPWpGaD
Flutamide—Oedema—Betamethasone—multiple sclerosis	0.000303	0.00142	CcSEcCtD
Flutamide—Oedema—Dexamethasone—multiple sclerosis	0.000303	0.00142	CcSEcCtD
Flutamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000303	0.00142	CcSEcCtD
Flutamide—Insomnia—Triamcinolone—multiple sclerosis	0.000302	0.00142	CcSEcCtD
Flutamide—Insomnia—Methylprednisolone—multiple sclerosis	0.000302	0.00141	CcSEcCtD
Flutamide—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000301	0.00401	CbGpPWpGaD
Flutamide—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000301	0.00401	CbGpPWpGaD
Flutamide—Ill-defined disorder—Prednisone—multiple sclerosis	0.0003	0.00141	CcSEcCtD
Flutamide—Feeling abnormal—Prednisolone—multiple sclerosis	0.0003	0.0014	CcSEcCtD
Flutamide—Anaemia—Prednisone—multiple sclerosis	0.000299	0.0014	CcSEcCtD
Flutamide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000297	0.00139	CcSEcCtD
Flutamide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000297	0.00139	CcSEcCtD
Flutamide—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000296	0.00396	CbGpPWpGaD
Flutamide—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000296	0.00396	CbGpPWpGaD
Flutamide—Malaise—Prednisone—multiple sclerosis	0.000292	0.00137	CcSEcCtD
Flutamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000291	0.00389	CbGpPWpGaD
Flutamide—Anorexia—Betamethasone—multiple sclerosis	0.000289	0.00135	CcSEcCtD
Flutamide—Anorexia—Dexamethasone—multiple sclerosis	0.000289	0.00135	CcSEcCtD
Flutamide—Fatigue—Triamcinolone—multiple sclerosis	0.000288	0.00135	CcSEcCtD
Flutamide—AHR—Adipogenesis—STAT3—multiple sclerosis	0.000288	0.00384	CbGpPWpGaD
Flutamide—Fatigue—Methylprednisolone—multiple sclerosis	0.000288	0.00135	CcSEcCtD
Flutamide—CYP1A1—Biological oxidations—CYP24A1—multiple sclerosis	0.000284	0.00379	CbGpPWpGaD
Flutamide—CYP1A1—Biological oxidations—CYP27B1—multiple sclerosis	0.000284	0.00379	CbGpPWpGaD
Flutamide—AR—Notch-mediated HES/HEY network—CD4—multiple sclerosis	0.000284	0.00379	CbGpPWpGaD
Flutamide—Vomiting—Mitoxantrone—multiple sclerosis	0.000282	0.00132	CcSEcCtD
Flutamide—CYP1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00028	0.00374	CbGpPWpGaD
Flutamide—CYP1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00028	0.00374	CbGpPWpGaD
Flutamide—Hypertension—Prednisone—multiple sclerosis	0.000279	0.00131	CcSEcCtD
Flutamide—Rash—Mitoxantrone—multiple sclerosis	0.000279	0.00131	CcSEcCtD
Flutamide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000279	0.00131	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—MAPK1—multiple sclerosis	0.000279	0.00372	CbGpPWpGaD
Flutamide—Headache—Mitoxantrone—multiple sclerosis	0.000278	0.0013	CcSEcCtD
Flutamide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000276	0.00129	CcSEcCtD
Flutamide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000275	0.00129	CcSEcCtD
Flutamide—Anxiety—Prednisone—multiple sclerosis	0.000275	0.00129	CcSEcCtD
Flutamide—Insomnia—Dexamethasone—multiple sclerosis	0.000274	0.00128	CcSEcCtD
Flutamide—Insomnia—Betamethasone—multiple sclerosis	0.000274	0.00128	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000274	0.00128	CcSEcCtD
Flutamide—Discomfort—Prednisone—multiple sclerosis	0.000272	0.00127	CcSEcCtD
Flutamide—Erythema—Methotrexate—multiple sclerosis	0.000271	0.00127	CcSEcCtD
Flutamide—AHR—Adipogenesis—TGFB1—multiple sclerosis	0.000267	0.00356	CbGpPWpGaD
Flutamide—Oedema—Prednisone—multiple sclerosis	0.000264	0.00124	CcSEcCtD
Flutamide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000264	0.00123	CcSEcCtD
Flutamide—Decreased appetite—Betamethasone—multiple sclerosis	0.000264	0.00123	CcSEcCtD
Flutamide—Nausea—Mitoxantrone—multiple sclerosis	0.000263	0.00123	CcSEcCtD
Flutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000263	0.00351	CbGpPWpGaD
Flutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000263	0.00351	CbGpPWpGaD
Flutamide—Fatigue—Betamethasone—multiple sclerosis	0.000262	0.00122	CcSEcCtD
Flutamide—Fatigue—Dexamethasone—multiple sclerosis	0.000262	0.00122	CcSEcCtD
Flutamide—Skin disorder—Prednisone—multiple sclerosis	0.000257	0.0012	CcSEcCtD
Flutamide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000253	0.00338	CbGpPWpGaD
Flutamide—Anorexia—Prednisone—multiple sclerosis	0.000252	0.00118	CcSEcCtD
Flutamide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000251	0.00117	CcSEcCtD
Flutamide—Anaemia—Methotrexate—multiple sclerosis	0.00025	0.00117	CcSEcCtD
Flutamide—Feeling abnormal—Betamethasone—multiple sclerosis	0.00025	0.00117	CcSEcCtD
Flutamide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00025	0.00117	CcSEcCtD
Flutamide—AHR—Adipogenesis—TNF—multiple sclerosis	0.000249	0.00333	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000248	0.00331	CbGpPWpGaD
Flutamide—Malaise—Methotrexate—multiple sclerosis	0.000244	0.00114	CcSEcCtD
Flutamide—Leukopenia—Methotrexate—multiple sclerosis	0.000242	0.00113	CcSEcCtD
Flutamide—CYP1B1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000241	0.00322	CbGpPWpGaD
Flutamide—Dizziness—Prednisolone—multiple sclerosis	0.00024	0.00113	CcSEcCtD
Flutamide—Asthenia—Triamcinolone—multiple sclerosis	0.00024	0.00112	CcSEcCtD
Flutamide—Asthenia—Methylprednisolone—multiple sclerosis	0.000239	0.00112	CcSEcCtD
Flutamide—Insomnia—Prednisone—multiple sclerosis	0.000239	0.00112	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.000237	0.00317	CbGpPWpGaD
Flutamide—Pruritus—Triamcinolone—multiple sclerosis	0.000237	0.00111	CcSEcCtD
Flutamide—Pruritus—Methylprednisolone—multiple sclerosis	0.000236	0.0011	CcSEcCtD
Flutamide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000232	0.0031	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000232	0.0031	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000232	0.0031	CbGpPWpGaD
Flutamide—Decreased appetite—Prednisone—multiple sclerosis	0.00023	0.00107	CcSEcCtD
Flutamide—Rash—Prednisolone—multiple sclerosis	0.000229	0.00107	CcSEcCtD
Flutamide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000229	0.00306	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000229	0.00306	CbGpPWpGaD
Flutamide—Dermatitis—Prednisolone—multiple sclerosis	0.000229	0.00107	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000229	0.00107	CcSEcCtD
Flutamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000228	0.00107	CcSEcCtD
Flutamide—Fatigue—Prednisone—multiple sclerosis	0.000228	0.00107	CcSEcCtD
Flutamide—Headache—Prednisolone—multiple sclerosis	0.000228	0.00107	CcSEcCtD
Flutamide—Discomfort—Methotrexate—multiple sclerosis	0.000228	0.00107	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000226	0.00302	CbGpPWpGaD
Flutamide—Constipation—Prednisone—multiple sclerosis	0.000226	0.00106	CcSEcCtD
Flutamide—Confusional state—Methotrexate—multiple sclerosis	0.000223	0.00104	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000221	0.00295	CbGpPWpGaD
Flutamide—Dizziness—Triamcinolone—multiple sclerosis	0.000221	0.00103	CcSEcCtD
Flutamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000221	0.00103	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.00022	0.00294	CbGpPWpGaD
Flutamide—AR—Notch-mediated HES/HEY network—STAT3—multiple sclerosis	0.00022	0.00294	CbGpPWpGaD
Flutamide—Feeling abnormal—Prednisone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Flutamide—Asthenia—Dexamethasone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Flutamide—Asthenia—Betamethasone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000217	0.00289	CbGpPWpGaD
Flutamide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000216	0.00101	CcSEcCtD
Flutamide—Nausea—Prednisolone—multiple sclerosis	0.000216	0.00101	CcSEcCtD
Flutamide—Pruritus—Dexamethasone—multiple sclerosis	0.000215	0.001	CcSEcCtD
Flutamide—Pruritus—Betamethasone—multiple sclerosis	0.000215	0.001	CcSEcCtD
Flutamide—Skin disorder—Methotrexate—multiple sclerosis	0.000214	0.001	CcSEcCtD
Flutamide—Vomiting—Triamcinolone—multiple sclerosis	0.000213	0.000995	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000213	0.00284	CbGpPWpGaD
Flutamide—Vomiting—Methylprednisolone—multiple sclerosis	0.000212	0.000993	CcSEcCtD
Flutamide—Rash—Triamcinolone—multiple sclerosis	0.000211	0.000987	CcSEcCtD
Flutamide—Dermatitis—Triamcinolone—multiple sclerosis	0.000211	0.000986	CcSEcCtD
Flutamide—Anorexia—Methotrexate—multiple sclerosis	0.00021	0.000985	CcSEcCtD
Flutamide—Rash—Methylprednisolone—multiple sclerosis	0.00021	0.000984	CcSEcCtD
Flutamide—Dermatitis—Methylprednisolone—multiple sclerosis	0.00021	0.000984	CcSEcCtD
Flutamide—Headache—Triamcinolone—multiple sclerosis	0.000209	0.00098	CcSEcCtD
Flutamide—Headache—Methylprednisolone—multiple sclerosis	0.000209	0.000978	CcSEcCtD
Flutamide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000208	0.000971	CcSEcCtD
Flutamide—Diarrhoea—Betamethasone—multiple sclerosis	0.000208	0.000971	CcSEcCtD
Flutamide—AHR—Adipogenesis—IL6—multiple sclerosis	0.000201	0.00268	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000201	0.00268	CbGpPWpGaD
Flutamide—Dizziness—Betamethasone—multiple sclerosis	0.000201	0.000939	CcSEcCtD
Flutamide—Dizziness—Dexamethasone—multiple sclerosis	0.000201	0.000939	CcSEcCtD
Flutamide—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.0002	0.00267	CbGpPWpGaD
Flutamide—Insomnia—Methotrexate—multiple sclerosis	0.0002	0.000935	CcSEcCtD
Flutamide—Nausea—Triamcinolone—multiple sclerosis	0.000199	0.000929	CcSEcCtD
Flutamide—Nausea—Methylprednisolone—multiple sclerosis	0.000198	0.000927	CcSEcCtD
Flutamide—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000197	0.00263	CbGpPWpGaD
Flutamide—Somnolence—Methotrexate—multiple sclerosis	0.000196	0.000919	CcSEcCtD
Flutamide—CYP1B1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000195	0.00261	CbGpPWpGaD
Flutamide—Vomiting—Dexamethasone—multiple sclerosis	0.000193	0.000903	CcSEcCtD
Flutamide—Vomiting—Betamethasone—multiple sclerosis	0.000193	0.000903	CcSEcCtD
Flutamide—Decreased appetite—Methotrexate—multiple sclerosis	0.000192	0.000898	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000192	0.00256	CbGpPWpGaD
Flutamide—Rash—Dexamethasone—multiple sclerosis	0.000191	0.000895	CcSEcCtD
Flutamide—Rash—Betamethasone—multiple sclerosis	0.000191	0.000895	CcSEcCtD
Flutamide—Dermatitis—Betamethasone—multiple sclerosis	0.000191	0.000894	CcSEcCtD
Flutamide—Dermatitis—Dexamethasone—multiple sclerosis	0.000191	0.000894	CcSEcCtD
Flutamide—Fatigue—Methotrexate—multiple sclerosis	0.00019	0.000891	CcSEcCtD
Flutamide—Headache—Betamethasone—multiple sclerosis	0.00019	0.000889	CcSEcCtD
Flutamide—Headache—Dexamethasone—multiple sclerosis	0.00019	0.000889	CcSEcCtD
Flutamide—AR—Gene Expression—ZNF746—multiple sclerosis	0.00019	0.00254	CbGpPWpGaD
Flutamide—Asthenia—Prednisone—multiple sclerosis	0.00019	0.000887	CcSEcCtD
Flutamide—Pruritus—Prednisone—multiple sclerosis	0.000187	0.000875	CcSEcCtD
Flutamide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000182	0.000852	CcSEcCtD
Flutamide—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000181	0.00242	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000181	0.00242	CbGpPWpGaD
Flutamide—Diarrhoea—Prednisone—multiple sclerosis	0.000181	0.000846	CcSEcCtD
Flutamide—Nausea—Betamethasone—multiple sclerosis	0.00018	0.000843	CcSEcCtD
Flutamide—Nausea—Dexamethasone—multiple sclerosis	0.00018	0.000843	CcSEcCtD
Flutamide—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000179	0.00238	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000179	0.00238	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000177	0.00236	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000177	0.00236	CbGpPWpGaD
Flutamide—Dizziness—Prednisone—multiple sclerosis	0.000175	0.000818	CcSEcCtD
Flutamide—AR—Gene Expression—PTBP1—multiple sclerosis	0.000174	0.00232	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000172	0.0023	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000172	0.00229	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000171	0.00228	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000168	0.00225	CbGpPWpGaD
Flutamide—Vomiting—Prednisone—multiple sclerosis	0.000168	0.000786	CcSEcCtD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000167	0.00223	CbGpPWpGaD
Flutamide—Rash—Prednisone—multiple sclerosis	0.000167	0.00078	CcSEcCtD
Flutamide—Dermatitis—Prednisone—multiple sclerosis	0.000166	0.000779	CcSEcCtD
Flutamide—Headache—Prednisone—multiple sclerosis	0.000165	0.000775	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	0.000162	0.00216	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.00016	0.00214	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.00016	0.00214	CbGpPWpGaD
Flutamide—Asthenia—Methotrexate—multiple sclerosis	0.000158	0.000741	CcSEcCtD
Flutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000157	0.0021	CbGpPWpGaD
Flutamide—Nausea—Prednisone—multiple sclerosis	0.000157	0.000734	CcSEcCtD
Flutamide—Pruritus—Methotrexate—multiple sclerosis	0.000156	0.000731	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000153	0.00204	CbGpPWpGaD
Flutamide—Diarrhoea—Methotrexate—multiple sclerosis	0.000151	0.000707	CcSEcCtD
Flutamide—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000148	0.00198	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000146	0.00195	CbGpPWpGaD
Flutamide—Dizziness—Methotrexate—multiple sclerosis	0.000146	0.000683	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—IL6—multiple sclerosis	0.000142	0.00189	CbGpPWpGaD
Flutamide—Vomiting—Methotrexate—multiple sclerosis	0.00014	0.000657	CcSEcCtD
Flutamide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.00014	0.00187	CbGpPWpGaD
Flutamide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.00014	0.00187	CbGpPWpGaD
Flutamide—Rash—Methotrexate—multiple sclerosis	0.000139	0.000652	CcSEcCtD
Flutamide—Dermatitis—Methotrexate—multiple sclerosis	0.000139	0.000651	CcSEcCtD
Flutamide—Headache—Methotrexate—multiple sclerosis	0.000138	0.000647	CcSEcCtD
Flutamide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000138	0.00184	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000138	0.00184	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000136	0.00182	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000136	0.00181	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	0.000134	0.00178	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	0.000132	0.00176	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—STAT3—multiple sclerosis	0.000132	0.00176	CbGpPWpGaD
Flutamide—AR—Gene Expression—U2AF2—multiple sclerosis	0.000132	0.00176	CbGpPWpGaD
Flutamide—AR—Gene Expression—HNRNPA1—multiple sclerosis	0.000132	0.00176	CbGpPWpGaD
Flutamide—Nausea—Methotrexate—multiple sclerosis	0.000131	0.000614	CcSEcCtD
Flutamide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000127	0.0017	CbGpPWpGaD
Flutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000121	0.00162	CbGpPWpGaD
Flutamide—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00012	0.00161	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—PGR—multiple sclerosis	0.000119	0.00159	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—SRM—multiple sclerosis	0.000112	0.00149	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000109	0.00146	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000109	0.00146	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000106	0.00142	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000106	0.00141	CbGpPWpGaD
Flutamide—AR—Gene Expression—ZFP36L1—multiple sclerosis	0.000104	0.00139	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000104	0.00139	CbGpPWpGaD
Flutamide—CYP1B1—Biological oxidations—POMC—multiple sclerosis	0.000104	0.00139	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.0001	0.00134	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	9.88e-05	0.00132	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	9.88e-05	0.00132	CbGpPWpGaD
Flutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.84e-05	0.00131	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	9.73e-05	0.0013	CbGpPWpGaD
Flutamide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.46e-05	0.00126	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.92e-05	0.00119	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.92e-05	0.00119	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	8.68e-05	0.00116	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	8.65e-05	0.00115	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—VDR—multiple sclerosis	8.32e-05	0.00111	CbGpPWpGaD
Flutamide—AR—Gene Expression—PABPC1—multiple sclerosis	8.07e-05	0.00108	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	8.03e-05	0.00107	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CYP27B1—multiple sclerosis	7.89e-05	0.00105	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CYP24A1—multiple sclerosis	7.89e-05	0.00105	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	7.86e-05	0.00105	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.71e-05	0.00103	CbGpPWpGaD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.67e-05	0.00102	CbGpPWpGaD
Flutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.3e-05	0.000975	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—SRM—multiple sclerosis	7.3e-05	0.000974	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—TNF—multiple sclerosis	7.29e-05	0.000973	CbGpPWpGaD
Flutamide—AR—Gene Expression—RPL5—multiple sclerosis	7.28e-05	0.000972	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—GPC5—multiple sclerosis	7.21e-05	0.000963	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.95e-05	0.000928	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.95e-05	0.000928	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—SRM—multiple sclerosis	6.89e-05	0.00092	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	6.76e-05	0.000903	CbGpPWpGaD
Flutamide—CYP3A5—Biological oxidations—POMC—multiple sclerosis	6.76e-05	0.000903	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	6.75e-05	0.000901	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	6.65e-05	0.000889	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	6.64e-05	0.000886	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	6.62e-05	0.000883	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	6.51e-05	0.000869	CbGpPWpGaD
Flutamide—CYP1A1—Biological oxidations—POMC—multiple sclerosis	6.39e-05	0.000853	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	6.3e-05	0.000841	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	6.3e-05	0.000841	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	6.2e-05	0.000828	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—RRM1—multiple sclerosis	5.98e-05	0.000798	CbGpPWpGaD
Flutamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.92e-05	0.00079	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—IL6—multiple sclerosis	5.88e-05	0.000785	CbGpPWpGaD
Flutamide—AR—Gene Expression—PGR—multiple sclerosis	5.73e-05	0.000765	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—SRM—multiple sclerosis	5.64e-05	0.000753	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	5.23e-05	0.000698	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	5.14e-05	0.000686	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	5.14e-05	0.000686	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	4.86e-05	0.000648	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	4.86e-05	0.000648	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.75e-05	0.000634	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—GPC5—multiple sclerosis	4.7e-05	0.000628	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.64e-05	0.000619	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—GPC5—multiple sclerosis	4.44e-05	0.000593	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—SRM—multiple sclerosis	4.4e-05	0.000587	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—POMC—multiple sclerosis	4.07e-05	0.000544	CbGpPWpGaD
Flutamide—AR—Gene Expression—VDR—multiple sclerosis	4e-05	0.000535	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.98e-05	0.000532	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	3.97e-05	0.000531	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	3.97e-05	0.000531	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—RRM1—multiple sclerosis	3.9e-05	0.00052	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.88e-05	0.000519	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—RRM1—multiple sclerosis	3.68e-05	0.000491	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—GPC5—multiple sclerosis	3.63e-05	0.000485	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.63e-05	0.000485	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—BCHE—multiple sclerosis	3.43e-05	0.000458	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—SRM—multiple sclerosis	3.39e-05	0.000453	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—MYC—multiple sclerosis	3.31e-05	0.000441	CbGpPWpGaD
Flutamide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.14e-05	0.00042	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	3.1e-05	0.000413	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	3.1e-05	0.000413	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.03e-05	0.000404	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—RRM1—multiple sclerosis	3.01e-05	0.000402	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.86e-05	0.000381	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—GPC5—multiple sclerosis	2.83e-05	0.000378	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.45e-05	0.000328	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.39e-05	0.000319	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.39e-05	0.000319	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—RRM1—multiple sclerosis	2.35e-05	0.000313	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.34e-05	0.000312	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—BCHE—multiple sclerosis	2.24e-05	0.000299	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.24e-05	0.000299	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.19e-05	0.000292	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—BCHE—multiple sclerosis	2.11e-05	0.000282	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—APOE—multiple sclerosis	2.07e-05	0.000276	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.01e-05	0.000268	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.83e-05	0.000244	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.82e-05	0.000243	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.81e-05	0.000242	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—POMC—multiple sclerosis	1.77e-05	0.000237	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.73e-05	0.000231	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—ALB—multiple sclerosis	1.62e-05	0.000216	CbGpPWpGaD
Flutamide—AR—Gene Expression—MYC—multiple sclerosis	1.59e-05	0.000213	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.56e-05	0.000209	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.43e-05	0.00019	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.35e-05	0.00018	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—APOE—multiple sclerosis	1.35e-05	0.00018	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—APOE—multiple sclerosis	1.27e-05	0.00017	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—POMC—multiple sclerosis	1.16e-05	0.000154	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—POMC—multiple sclerosis	1.09e-05	0.000146	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—ALB—multiple sclerosis	1.05e-05	0.000141	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—APOE—multiple sclerosis	1.04e-05	0.000139	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.04e-05	0.000139	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—ALB—multiple sclerosis	9.96e-06	0.000133	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—POMC—multiple sclerosis	8.94e-06	0.000119	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—ALB—multiple sclerosis	8.15e-06	0.000109	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—APOE—multiple sclerosis	8.11e-06	0.000108	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—POMC—multiple sclerosis	6.97e-06	9.3e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—ALB—multiple sclerosis	6.35e-06	8.48e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—APOE—multiple sclerosis	6.26e-06	8.36e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—POMC—multiple sclerosis	5.38e-06	7.18e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—ALB—multiple sclerosis	4.9e-06	6.54e-05	CbGpPWpGaD
